Abstract CT029: Safety and clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 trial in subjects with recurrent or advanced uterine serous carcinoma (USC) Cancer Res, 82 (12_Supplement) (2022), p. CT029 CrossrefGoogle Scholar [19] C. Muñoz-Fontela, A. Ma...
Bone is one of the most common metastatic areas in the cancer patient. Bone metastasis is the major cause to deteriorate the quality of life due to severe pain, walking difficulty, paraplegia, and pathologic fracture. To maintain patient’s general condi
Paclitaxel represents an established active cytotoxic agent against a wide variety of advanced solid tumours, including gynaecological cancers such as ovarian, uterine, and cervical malignancies. Beyond its early documented activity in relapsed ovarian cancer (Eisenhauer et al, 1994), there are a small...
Patient preference, performance status, life expectancy, severity of disease, and expected benefit from surgery all impact medical decision-making. MBO has been described as an end-of-life heralding event. It occurs in approximately 3-11% of patients who have a diagnosis of endometrial cancer (...
biliary tract cancer, colorectal cancer, non-small-cell lung cancer, uterine cancer and bladder cancer1. HER2 is a prognostic biomarker of breast cancer, with HER2 overexpression/amplification associated with poorer outcomes and higher rates of disease relapse and mortality versus HER2-negative cases2...
known brain metastases or a secondary malignancy, history of another primary malignant disease other than in situ carcinoma of the uterine cervix or adequately treated basal cell skin cancer, active infection or any other concomitant severe clinical condition making implementation of the protocol including...
A prediction model of survival for patients with bone metastasis from uterine corpus cancer. Jpn. J. Clin. Oncol. 2016, 46, 973–978. [Google Scholar] [CrossRef] [PubMed] Kerin, R. Metastatic Tumors of the Hand. JBJS 1983, 65, 1331–1335. [Google Scholar] [CrossRef] Chakera, A.H...